Reporting season is over and now we get to pick through the pieces to see if there are any opportunities.
Although there wasn’t a strong reaction to the National Veterinary Care Ltd (ASX: NVL) report on the day, it had already warned that the result would be somewhat disappointing and the share price had fallen.
Whilst there was a solid improvement of revenue by 26% to $84.2 million and 25.6% growth of statutory earnings per share (EPS) to 10.63 cents in the report, the decline of the underlying earnings before interest, tax, depreciation and amortisation (EBITDA) margin from 18.1% to 15.9% was a drag on the result.
However, the 2.51% GP organic revenue growth, 76% growth of pet membership, 20% growth of the management services division and the expanding network of vet clinics were all pleasing factors in FY18 and points to a better FY19.
Indeed, management said that in July 2018 organic growth was 2.5%. Plus, management guided that revenue would be 25% higher in FY19 and that the EBITDA margin would stabilise.
This is all positive, particularly with the company announcing another acquisition earlier this week. The new acquisition is based in New South Wales and is expected to settle by the end of October 2018.
According to National Vet Care, the acquisition generates annual revenue of $1.6 million and annual earnings before interest and tax (EBIT) of $0.45 million – an impressive margin when you consider National Vet Care’s overall underlying EBITDA margin was 15.9% in FY18.
The total cost of this acquisition is $2.25 million, including a deferred component of $0.45 million subject to earnout conditions.
Once this acquisition is integrated the company will have a total of 68 clinics across its network.
I think that the beaten-down share price of National Vet Care represents a decent opportunity to buy into this growing business. A roll-up strategy isn’t the most attractive thesis out there, but the company’s bottom line continues to grow.
It can easily grow to 100, 125 or perhaps more clinics in the medium-term as long as it can find the right targets.
It’s trading at roughly 20x FY19’s estimated earnings, which I think is a pretty good price for this growing business.
Want some more growth ideas for your portfolio? These top shares have all created great wealth for shareholders and are predicted to keep going up!
For many, blue chip stocks mean stability, profitability and regular dividends, often fully franked..
But knowing which blue chips to buy, and when, can be fraught with danger.
The Motley Fool’s in-house analyst team has poured over thousands of hours worth of proprietary research to bring you the names of "The Motley Fool’s Top 3 Blue Chip Stocks for 2018."
Each one pays a fully franked dividend. Each one has not only grown its profits, but has also grown its dividend. One increased it by a whopping 33%, while another trades on a grossed up (fully franked) dividend yield of almost 7%.
The names of these Top 3 ASX Blue Chips are included in this specially prepared free report. But you will have to hurry. Depending on demand – and how quickly the share prices of these companies moves – we may be forced to remove this report.
Click here to claim your free report.
Motley Fool contributor Tristan Harrison owns shares of NATVETCARE FPO. The Motley Fool Australia owns shares of NATVETCARE FPO. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.